Tau proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Li, Zhi Hua ^a,b   Xiong, Qiu Yun ^a   Tu, Jian Hong ^c   Gong, Yu ^a   Qiu, Wei ^c   Zhang, Hui Qin ^a   Wei, Wen Shong ^a   Hou, Yi Feng ^d   Cui, Wei Qi ^a  

^a Third Hospital of Nanchang   (China)

^b NANCHANG UNIVERSITY   (China)

^c Pathology Departments   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

Breast cancer; Drug resistance; Tau protein; Taxane

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MICROTUBULE ASSOCIATED PROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53; TAU PROTEIN; TAXANE DERIVATIVE; BRIDGED COMPOUND; TAXANE; TAXOID; TP53 PROTEIN, HUMAN;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER REGRESSION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADJUVANT THERAPY; BREAST TUMOR; GENETICS; METHODOLOGY; MIDDLE AGED; YOUNG ADULT; BREAST NEOPLASMS; PROCEDURES;

ADULT; AGED; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAU PROTEINS; TAXOIDS; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84877673989     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0591-y     Document Type: Article

References (31)

1. Qiu J, Yang M, Chen W, Gao X, Liu S, Shi S, Xie B. Prevalence and correlates of major depressive disorder in breast cancer survivors in Shanghai, China. Psychooncology. 2011; doi:10.1002/pon.2075.
2. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemo resistant breast cancer. Biochim Biophys Acta. 2008;1785(2):96-132.
3. Russell P, Hennessy BT, Li J, Carey MS, Bast RC, Freeman T, Venkitaraman AR. Cyclin G1 regulates the outcome of taxaneinduced mitotic checkpoint arrest. Oncogene. 2012;31(19):2450-60. doi:10.1038/onc.2011.431.
4. Qin YY, Li H, Guo XJ, Ye XF, Wei X, Zhou YH, Zhang XJ, Wang C, Qian W, Lu J, He J. Adjuvant chemotherapy, with or without Taxanes, in Early or operable breast cancer: a metaanalysis of 19 randomized trials with 30698 patients. PLoS ONE. 2011;6(11):e26946.
5. Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol. 2007; 18(Suppl 12): xii15-xii20.
6. Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene. 2000;19(27):3078-85.
7. Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Marana HR, Tiezzi MG. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer. 2007;7:36.
8. Veitia R, Bissery MC, Martinez C, Fellous A. Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice. Br J Cancer. 1998;78(7):871-7.
9. Smoter M, Bodnar L, Duchnowska R, Stec R, Grala B, Szczylik C. The role of Tau protein in resistance to paclitaxel. Cancer Chemother Pharmacol. 2011;68(3):553-7.
10. Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC cancer staging manual. CA Cancer J Clin. 2006; 56(1):37-47, quiz 50-1.
11. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320-7.
12. Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American society of clinical oncology/college of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784-95.
13. Kamil M, Yusuf N, Khalid I, Islam R, Biswas M, Hashim H. Association between HER-2/neu over-expression and clinicopathologic parameters of breast cancer in northern Malaysia. Ceylon Med J. 2010;55(1):9-13.
14. Mathieu MC, Rouzier R, Llombart-Cussac A, Sideris L, Koscielny S, Travagli JP, Contesso G, Delaloge S, Spielmann M. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer. 2004;40(3):342-51.
15. Bidard FC, Matthieu MC, Chollet P, Raoefils I, Abrial C, Dômont J, Spielmann M, Delaloge S, André F, Penault-Llorca F. p53 Status and efficacy of primary anthracyclines/alkylating agentbased regimen according to breast cancer molecular classes. Ann Oncol. 2008;19(7):1261-5.
16. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA. 2005;102(23):8315-20.
17. Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, Fisher E, Wolmark N, Deutsch M, Montague E, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985;312(11):665-73.
18. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003;21(17):3357-65.
19. Gajria D, Seidman A, Dang C. Adjuvant taxanes: more to the story. Clin Breast Cancer. 2010;10(Suppl 2):S41-9.
20. Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L. Microtubule associated protein(MAP)-Tau: a novelmediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle. 2005;4(9):1149-52.
21. Spicakova T, O'Brien MM, Duran GE, Sweet-Cordero A, Sikic BI. Expression and silencing of microtubule-associated protein Tau in breast cancer cells. Mol Cancer Ther. 2010;9(11):2970-81.
22. Ikeda H, Taira N, Hara F, Fujita T, Yamamoto H, Soh J, Toyooka S, Nogami T, Shien T, Doihara H, Miyoshi S. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Res. 2010;12(3):R43.
23. Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptorpositive breast cancer. Clin Cancer Res. 2007;13(7):2061-7.
24. Tanaka S, Nohara T, Iwamoto M, Sumiyoshi K, Kimura K, Takahashi Y, Tanigawa N. Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer. Cancer Chemother Pharmacol. 2008;64(2):341-6.
25. Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, Hsu C, Kuo WH, Chang KJ, Lin CH, Cheng AL. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. Jpn J Clin Oncol. 2010;40(4):286-93.
26. Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhäberle E, Holtrich U, von Minckwitz G, Kaufmann M. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: hER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast. 2007;16:86-93.
27. Pusztai L, Jeong JH, Gong Y, Ross JS, Kim C, Paik S, Rouzier R, Andre F, Hortobagyi GN, Wolmark N, Symmans WF. Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol. 2009;27(26):4287-92.
28. Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic cooperative oncology group trial. Breast Cancer Res Treat. 2009;116(1):131-43.
29. Baquero MT, Lostritto K, Gustavson MD, Bassi KA, Appia F, Camp RL, Molinaro AM, Harris LN, Rimm DL. Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts. Breast Cancer Res. 2011;13(5):R85.
30. Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic cooperative oncology group trial. Breast Cancer Res Treat. 2009;116(1):131-43.
31. Loi S, de Azambuja E, Pugliano L, Sotiriou C, Piccart MJ. HER2-overexpressing breast cancer: time for the cure with less chemotherapy? Curr Opin Oncol. 2011;23(6):547-58.